ClinicalTrials.gg
CompletedNCT03003533Updated Dec 30, 2024Results posted

A Gene Transfer Study for Hemophilia A

A Phase 1/2 interventional study of SPK-8011 in Hemophilia A, sponsored by Spark Therapeutics, Inc.. Completed at 16 sites in 5 countries. Open to male participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-12-30.

Sponsored by Spark Therapeutics, Inc. (part of Hoffmann-La Roche) · Phase 1/2, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
25
Allocation
Non-randomized
Ages
18 Years and older
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 25 studies in Hemophilia A by Hoffmann-La Roche — 5 open to participants now, 8 under way, 4 of them phase 3. Hemophilia A · Hoffmann-La Roche.

Enrollment
14th of 20
25 · median 58
Started
2017
with 2 others
Phase 1/2
4 of 25
2 open now
Registered
6th of 25
by date

Among the 25 studies in Hemophilia A by Hoffmann-La Roche, this one is the 14th largest by enrollment of the 20 interventional ones that give a count, is one of 3 that started in 2017, is one of 4 in phase 1/2, and was the 6th registered.

Hemophilia A

845 studies on the registry are indexed under Hemophilia A; 137 are open to participants now.

Browse Hemophilia A studies →

Open to participants now

5 of the 25 studies in Hemophilia A by Hoffmann-La Roche are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

Who these studies take

Of the 88 Hemophilia A studies recruiting now, 52 (59%) set no upper age limit and 31 (35%) stop at 75 or younger; 56 take children under 18; 10 take healthy volunteers.

This study: 18 Years and older · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 25 studies in Hemophilia A by Hoffmann-La Roche, or all of them as a file.
02

Study summary

This clinical research study is being conducted by Spark Therapeutics, Inc. to determine the safety and efficacy of the factor VIII gene transfer treatment with SPK-8011 in individuals with hemophilia A.

Read the detailed description

Hemophilia A is a condition in which blood is unable to clot effectively. It is caused by a mutation or deletion in the gene that is responsible for producing blood-clotting factor VIII protein. Individuals with hemophilia A suffer from repeated bleeding episodes, often into the joints, which can cause chronic joint disease and sometime results in death due to the inability of the blood to clot efficiently. This chronic joint disease can have significant physical, psychosocial, and quality-of-life effects, including financial burden. The current standard of care includes the use of factor-based therapies which are given either as prophylaxis or to treat bleeding, as well as new non-factor prophylaxis therapies.

03

Conditions studied

  • Hemophilia A

Keywords

  • Adeno-Associated Virus (AAV)
  • Blood Coagulation Disorders
  • Blood Coagulation Disorders, Inherited
  • Coagulation Protein Disorders
  • Factor VIII (FVIII)
  • Factor VIII (FVIII) Deficiency
  • Factor VIII (FVIII) Gene
  • Factor VIII (FVIII) Protein
  • Genetic Diseases, Inborn
  • Genetic Diseases, X-Linked
  • Gene Therapy
  • Gene Transfer
  • Hematologic Diseases
  • Hemorrhagic Disorders
  • Recombinant
  • Vector
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Males age 18 years or older
  • Confirmed diagnosis of hemophilia A as evidenced by their medical history with baseline FVIII activity levels \<=2%
  • Have received >150 exposure days (EDs) to FVIII concentrates or cryoprecipitate
  • Have no prior history of allergic reaction to any FVIII product
  • Have no measurable inhibitor against FVIII as assessed by the central laboratory and have no prior history of inhibitors to FVIII protein and no clinical signs or symptoms of decreased response to FVIII administration
  • Agree to use reliable barrier

Exclusion criteria

Exclusion Criteria:

  • Evidence of active or C
  • Currently on antiviral therapy for hepatitis B or C
  • Have significant underlying liver disease
  • Have serological evidence* of -1 or HIV-2 with ≤200/mm3 and who are on an antiretroviral drug regimen (* participants who are HIV+ and stable with CD4 count >200/mm3 and undetectable viral load are eligible to enroll)
  • Have detectable antibodies reactive with AAV-Spark200 capsid
  • Participated in a gene transfer trial within the last 52 weeks or in a clinical trial with an product within the last 12 weeks
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

CD4 count

The number of CD4 cells, a type of white blood cell, in a given amount of blood. It is used to follow how well the immune system is doing in HIV.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
25 participants (actual)

Study arms

  • Experimental
    SPK-8011 5x10^11 vg/kg

    Participants received a single intravenous (IV) infusion of SPK-8011 5x10\^11 vector genomes per kilogram (vg/kg) body weight.

    Genetic: SPK-8011

  • Experimental
    SPK-8011 1x10^12 vg/kg

    Participants received a single IV infusion of SPK-8011 1x10\^12 vg/kg.

    Genetic: SPK-8011

  • Experimental
    SPK-8011 2x10^12 vg/kg

    Participants received a single IV infusion of SPK-8011 2x10\^12 vg/kg.

    Genetic: SPK-8011

  • Experimental
    SPK-8011 1.5x10^12 vg/kg

    Participants received a single IV infusion of SPK-8011 1.5x10\^12 vg/kg.

    Genetic: SPK-8011

Interventions

  • GeneticSPK-8011

    A novel, bio-engineered, recombinant adeno-associated viral vector carrying human factor VIII gene

06

What researchers measure

Primary outcomes

  1. Number of Participants With Treatment-emergent Adverse Events (TEAEs)

    An adverse event (AE) was defined as any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. Serious adverse events (SAEs) were defined as adverse events that result in death, are life-threatening, require inpatient hospitalization or prolongation of existing hospitalization, result in persistent or significant disability or incapacity, are a congenital anomaly or birth defect, or are an important medical event that jeopardized participant and required medical intervention to prevent 1 of the outcomes listed in this definition. A TEAE is defined as an AE with an onset date on or following SPK-8011 administration. A summary of other non-serious AEs and all serious AEs, regardless of causality is located in Reported AE section.

    Time frame: From date of first dose to Week 52/End of Study (EOS) Visit

  2. Number of Participants Who Received Corticosteroids for Presumed Immune Response

    Time frame: Up to Week 52/EOS Visit

  3. Peak Factor VIII (FVIII) Activity Levels Assessed by One-Stage Coagulation Assay (OSA)

    Median peak FVIII activity up to Week 52

    Time frame: Up to Week 52/EOS visit

  4. Nominal FVIII Level by OSA at Week 52/EOS

    Steady-state FVIII activity measured by median FVIII levels at week 52 by OSA.

    Time frame: Up to Week 52/EOS Visit

  5. Spontaneous Bleeds Annualized Bleeding Rate

    Time frame: Week 5 up to Week 52/EOS Visit

  6. Total Annualized FVIII Infusion Rate

    Time frame: Week 5 up to Week 52/EOS Visit

Secondary outcomes

  1. Time to Achieve Peak FVIII Activity Level

    Time frame: Up to Week 52/EOS Visit

  2. Number of Participants With Vector-shedding Confirmed Below Quantifiable Limits (BQL) of SPK-8011-101 in Bodily Fluids

    Time frame: Up to Week 52/EOS Visit

  3. Incidence of Immune Response to the BDD-hFVIII Transgene

    Time frame: Up to Week 52/EOS Visit

07

Results

Posted Dec 30, 2024

Participant flow

Participant flow — Overall Study
MilestoneSPK-8011 5x10^11 vg/kgSPK-8011 1x10^12 vg/kgSPK-8011 2x10^12 vg/kgSPK-8011 1.5x10^12 vg/kg
Started23911
Received at least 1 dose of study drug23911
Completed23911
Not completed0000

Outcome measures

PrimaryNumber of Participants With Treatment-emergent Adverse Events (TEAEs)

An adverse event (AE) was defined as any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. Serious adverse events (SAEs) were defined as adverse events that result in death, are life-threatening, require inpatient hospitalization or prolongation of existing hospitalization, result in persistent or significant disability or incapacity, are a congenital anomaly or birth defect, or are an important medical event that jeopardized participant and required medical intervention to prevent 1 of the outcomes listed in this definition. A TEAE is defined as an AE with an onset date on or following SPK-8011 administration. A summary of other non-serious AEs and all serious AEs, regardless of causality is located in Reported AE section.

Time frame:
From date of first dose to Week 52/End of Study (EOS) Visit
Reported as:
Count of participants · Participants
Number of Participants With Treatment-emergent Adverse Events (TEAEs)
ParticipantsSPK-8011 5x10^11 vg/kgSPK-8011 1x10^12 vg/kgSPK-8011 2x10^12 vg/kgSPK-8011 1.5x10^12 vg/kg
Number of Participants With Treatment-emergent Adverse Events (TEAEs)23911
PrimaryNumber of Participants Who Received Corticosteroids for Presumed Immune Response
Time frame:
Up to Week 52/EOS Visit
Reported as:
Count of participants · Participants
Number of Participants Who Received Corticosteroids for Presumed Immune Response
ParticipantsSPK-8011 5x10^11 vg/kgSPK-8011 1x10^12 vg/kgSPK-8011 2x10^12 vg/kgSPK-8011 1.5x10^12 vg/kg
Number of Participants Who Received Corticosteroids for Presumed Immune Response02710
PrimaryPeak Factor VIII (FVIII) Activity Levels Assessed by One-Stage Coagulation Assay (OSA)

Median peak FVIII activity up to Week 52

Time frame:
Up to Week 52/EOS visit
Reported as:
Median · percentage of normal activity
Peak Factor VIII (FVIII) Activity Levels Assessed by One-Stage Coagulation Assay (OSA)
percentage of normal activitySPK-8011 5x10^11 vg/kgSPK-8011 1x10^12 vg/kgSPK-8011 2x10^12 vg/kgSPK-8011 1.5x10^12 vg/kg
Peak Factor VIII (FVIII) Activity Levels Assessed by One-Stage Coagulation Assay (OSA)11.5 (11 to 12)20.0 (6 to 24)38.7 (7 to 209)55.1 (31 to 112)
PrimaryNominal FVIII Level by OSA at Week 52/EOS

Steady-state FVIII activity measured by median FVIII levels at week 52 by OSA.

Time frame:
Up to Week 52/EOS Visit
Reported as:
Median · percentage of normal activity
Nominal FVIII Level by OSA at Week 52/EOS
percentage of normal activitySPK-8011 5x10^11 vg/kgSPK-8011 1x10^12 vg/kgSPK-8011 2x10^12 vg/kgSPK-8011 1.5x10^12 vg/kg
Nominal FVIII Level by OSA at Week 52/EOS5.4 (4.7 to 6.1)7.8 (3.0 to 13.9)8.4 (3.0 to 19.7)4.1 (3.0 to 11.9)
PrimarySpontaneous Bleeds Annualized Bleeding Rate
Time frame:
Week 5 up to Week 52/EOS Visit
Reported as:
Median · annualized number of bleeding events
Spontaneous Bleeds Annualized Bleeding Rate
annualized number of bleeding eventsSPK-8011 5x10^11 vg/kgSPK-8011 1x10^12 vg/kgSPK-8011 2x10^12 vg/kgSPK-8011 1.5x10^12 vg/kg
Spontaneous Bleeds Annualized Bleeding RateNA (NA to NA)0.3 (0.2 to 0.6)0.0 (0.0 to 1.4)0.0 (0.0 to 0.7)
PrimaryTotal Annualized FVIII Infusion Rate
Time frame:
Week 5 up to Week 52/EOS Visit
Reported as:
Mean · total annualized FVIII infusions
Total Annualized FVIII Infusion Rate
total annualized FVIII infusionsSPK-8011 5x10^11 vg/kgSPK-8011 1x10^12 vg/kgSPK-8011 2x10^12 vg/kgSPK-8011 1.5x10^12 vg/kg
Total Annualized FVIII Infusion Rate0.3 ± 0.403.6 ± 3.187.4 ± 7.931.6 ± 1.81
SecondaryTime to Achieve Peak FVIII Activity Level
Time frame:
Up to Week 52/EOS Visit
Reported as:
Mean · days
Time to Achieve Peak FVIII Activity Level
daysSPK-8011 5x10^11 vg/kgSPK-8011 1x10^12 vg/kgSPK-8011 2x10^12 vg/kgSPK-8011 1.5x10^12 vg/kg
Time to Achieve Peak FVIII Activity Level279.5 ± 58.69141.0 ± 151.7956.4 ± 19.8454.6 ± 33.74
SecondaryNumber of Participants With Vector-shedding Confirmed Below Quantifiable Limits (BQL) of SPK-8011-101 in Bodily Fluids
Time frame:
Up to Week 52/EOS Visit
Reported as:
Count of participants · Participants
Number of Participants With Vector-shedding Confirmed Below Quantifiable Limits (BQL) of SPK-8011-101 in Bodily Fluids
ParticipantsSPK-8011 5x10^11 vg/kgSPK-8011 1x10^12 vg/kgSPK-8011 2x10^12 vg/kgSPK-8011 1.5x10^12 vg/kg
Peripheral blood mononuclear cells (PBMCs)23911
Saliva23910
Semen22811
Serum23810
Urine23910
SecondaryIncidence of Immune Response to the BDD-hFVIII Transgene
Time frame:
Up to Week 52/EOS Visit
Reported as:
Count of participants · Participants
Incidence of Immune Response to the BDD-hFVIII Transgene
ParticipantsSPK-8011 5x10^11 vg/kgSPK-8011 1x10^12 vg/kgSPK-8011 2x10^12 vg/kgSPK-8011 1.5x10^12 vg/kg
Incidence of Immune Response to the BDD-hFVIII Transgene0000

Adverse events

Collected over From date of first dose up to Week 52. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
SPK-8011 5x10^11 vg/kg0/2 (0%)0/2 (0%)2/2 (100%)
SPK-8011 1x10^12 vg/kg0/3 (0%)1/3 (33.3%)3/3 (100%)
SPK-8011 2x10^12 vg/kg0/9 (0%)1/9 (11.1%)9/9 (100%)
SPK-8011 1.5x10^12 vg/kg0/11 (0%)3/11 (27.3%)11/11 (100%)
Most frequent serious events
Most frequent serious events
EventSPK-8011 5x10^11 vg/kgSPK-8011 1x10^12 vg/kgSPK-8011 2x10^12 vg/kgSPK-8011 1.5x10^12 vg/kg
AppendicitisInfections and infestations0/21/30/90/11
Transaminases IncreasedInvestigations0/20/31/90/11
Abdominal Pain UpperGastrointestinal disorders0/20/30/91/11
HypersensitivityImmune system disorders0/20/30/91/11
RhabdomyolysisMusculoskeletal and connective tissue disorders0/20/30/91/11
Most frequent other events
Showing 10 of 128
Most frequent other events
EventSPK-8011 5x10^11 vg/kgSPK-8011 1x10^12 vg/kgSPK-8011 2x10^12 vg/kgSPK-8011 1.5x10^12 vg/kg
Normocytic AnaemiaBlood and lymphatic system disorders1/20/30/90/11
ConjunctivitisInfections and infestations1/20/30/91/11
Pulpitis DentalInfections and infestations1/20/30/90/11
Iron DeficiencyMetabolism and nutrition disorders1/20/30/90/11
Alanine Aminotransferase IncreasedInvestigations0/20/31/95/11
Transaminases IncreasedInvestigations0/20/32/95/11
ConstipationGastrointestinal disorders0/20/30/94/11
Upper Respiratory Tract InfectionInfections and infestations0/20/31/94/11
HeadacheNervous system disorders0/20/31/94/11
InsomniaPsychiatric disorders0/20/32/94/11

Baseline characteristics

The Full Analysis Set included all participants who received the infusion of SPK-8011.

Age, Categorical
Age, Categorical(Participants)SPK-8011 5x10^11 vg/kgSPK-8011 1x10^12 vg/kgSPK-8011 2x10^12 vg/kgSPK-8011 1.5x10^12 vg/kgTotal
<=18 years00000
Between 18 and 65 years2391125
>=65 years00000
Sex: Female, Male
Sex: Female, Male(Participants)SPK-8011 5x10^11 vg/kgSPK-8011 1x10^12 vg/kgSPK-8011 2x10^12 vg/kgSPK-8011 1.5x10^12 vg/kgTotal
Female00000
Male2391125
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)SPK-8011 5x10^11 vg/kgSPK-8011 1x10^12 vg/kgSPK-8011 2x10^12 vg/kgSPK-8011 1.5x10^12 vg/kgTotal
Hispanic or Latino00000
Not Hispanic or Latino2391125
Unknown or Not Reported00000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)SPK-8011 5x10^11 vg/kgSPK-8011 1x10^12 vg/kgSPK-8011 2x10^12 vg/kgSPK-8011 1.5x10^12 vg/kgTotal
American Indian or Alaska Native00000
Asian00000
Native Hawaiian or Other Pacific Islander00000
Black or African American01012
White2291023
More than one race00000
Unknown or Not Reported00000
08

Study locations

16 sites
  • University of California Davis - Hemostasis and Thrombosis Center
    Sacramento, California 94817, United States
  • University of Florida Health
    Gainesville, Florida 32610, United States
  • Boston Children's Hospital
    Boston, Massachusetts 02115, United States
  • Mississippi Center for Advanced Medicine
    Madison, Mississippi 39110, United States
  • Weill Cornell Medicine-Comprehensive Center for Hemophilia and Coagulation Disorders
    New York, New York 10065, United States
  • Oregon Health & Science University
    Portland, Oregon 97239, United States
  • Pennsylvania State University Milton S. Hershey Medical Center
    Hershey, Pennsylvania 10733, United States
  • Children's Hospital of Philadelphia
    Philadelphia, Pennsylvania 19104, United States
  • Jefferson University Hospitals
    Philadelphia, Pennsylvania 19107, United States
  • Hemophilia Center of Western Pennsylvania
    Pittsburgh, Pennsylvania 15213, United States
  • Virginia Commonwealth University School of Medicine
    Richmond, Virginia 23219, United States
  • Royal Prince Alfred Hosptial
    Camperdown, New South Wales 2050, Australia
  • The Alfred Hospital
    Melbourne, 3004, Australia
  • McMaster University Medical Centre and Juravinski Hospital
    Hamilton, Ontario L8N 3Z5, Canada
  • Chaim Sheba Center
    Ramat Gan, Tel Hashomer 526000, Israel
  • Mahidol University - Ramathibody Hospital
    Bangkok, 10400, Thailand
09

References and documents

Publications

  • George LA, Monahan PE, Eyster ME, Sullivan SK, Ragni MV, Croteau SE, Rasko JEJ, Recht M, Samelson-Jones BJ, MacDougall A, Jaworski K, Noble R, Curran M, Kuranda K, Mingozzi F, Chang T, Reape KZ, Anguela XM, High KA. Multiyear Factor VIII Expression after AAV Gene Transfer for Hemophilia A. N Engl J Med. 2021 Nov 18;385(21):1961-1973. doi: 10.1056/NEJMoa2104205. PubMed 34788507 ↗
  • Ran G, Chen X, Xie Y, Zheng Q, Xie J, Yu C, Pittman N, Qi S, Yu FX, Agbandje-McKenna M, Srivastava A, Ling C. Site-Directed Mutagenesis Improves the Transduction Efficiency of Capsid Library-Derived Recombinant AAV Vectors. Mol Ther Methods Clin Dev. 2020 Mar 13;17:545-555. doi: 10.1016/j.omtm.2020.03.007. eCollection 2020 Jun 12. PubMed 32258217 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Undecided

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jan 2017 to primary completion in Dec 2023, 82 months.

Results were first posted in Dec 2024, 1 year after primary completion.

Of 20 phase 1/2 interventional studies under Hemophilia A, half reached primary completion within 76 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 94. This study's 82 months is close to that.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 16, 2016
First posted
Dec 28, 2016
StartActual
Jan 26, 2017
Primary completionActual
Dec 5, 2023
CompletionActual
Dec 5, 2023
Results first posted
Dec 30, 2024
Last update
Dec 30, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 30, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03003533
Responsible party
Sponsor
First posted
Dec 28, 2016
Start date
Jan 26, 2017
Primary completion
Dec 5, 2023
Completion
Dec 5, 2023
Results posted
Dec 30, 2024
Last update
Dec 30, 2024

Study contacts

Clinical Trial Director
study director · Spark Therapeutics, Inc.

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion